Bone is the most frequent site of metastases of prostate cancer and is almost always the first and frequently the only site of metastases where disease will progress to stage D3. In addition, the number of skeletal metastatic foci is the most powerful independent prognostic factor of limited response to hormone ablation therapy and poor survival of patients with advanced prostate cancer. Furthermore, disease progression frequently occurs in the osteoblastic metastases, even though androgen ablation therapy still provides adequate and sustained control of disease at the primary site. Notably, the management of metastatic disease onto bones has traditionally relied on therapeutic modalities, which almost exclusively aim at directly inducing cancer cell death. However, accumulating pieces of evidence, from both the clinical and the basic research front, point to major limitations of this conventional approach. The in vivo response of malignant cells to anticancer therapies is directly influenced by the local microenvironment in which they metastasize. In particular, organ sites frequently involved in metastatic diseases, such as the bones, appear to confer to metastatic cells protection from anticancer drug-induced apoptosis. This protection is mediated by soluble growth factors and cytokines released by the normal cellular constituents of the host tissue microenvironment. The characterization of bone microenvironment-related survival factors has led to the development of a novel hormone manipulation which can re-introduce clinical responses in patients with stage D3 prostate cancer.

This article has been cited by other articles:

				M. KARALAKI, S. FILI, A. PHILIPPOU, and M. KOUTSILIERIS Muscle Regeneration: Cellular and Molecular Events In Vivo, September 1, 2009; 23(5): 779 - 796. [Abstract] [Full Text] [PDF]

				G. Wang, S. Haile, B. Comuzzi, A. H. Tien, J. Wang, T. M.K. Yong, A. E. Jelescu-Bodos, N. Blaszczyk, R. L. Vessella, B. A. Masri, et al. Osteoblast-Derived Factors Induce an Expression Signature that Identifies Prostate Cancer Metastasis and Hormonal Progression Cancer Res., April 15, 2009; 69(8): 3433 - 3442. [Abstract] [Full Text] [PDF]

				C. S. Mitsiades, C. Rouleau, C. Echart, K. Menon, B. Teicher, M. Distaso, A. Palumbo, M. Boccadoro, K. C. Anderson, M. Iacobelli, et al. Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias Clin. Cancer Res., February 15, 2009; 15(4): 1210 - 1221. [Abstract] [Full Text] [PDF]

				N. PISSIMISSIS, E. PAPAGEORGIOU, P. LEMBESSIS, A. ARMAKOLAS, and M. KOUTSILIERIS The Glutamatergic System Expression in Human PC-3 and LNCaP Prostate Cancer Cells Anticancer Res, January 1, 2009; 29(1): 371 - 377. [Abstract] [Full Text] [PDF]

				G. Vlotides, T. Eigler, and S. Melmed Pituitary Tumor-Transforming Gene: Physiology and Implications for Tumorigenesis Endocr. Rev., April 1, 2007; 28(2): 165 - 186. [Abstract] [Full Text] [PDF]